Shots:

• The TRACK-TBI study evaluated its blood test technology in 450 patients admitted to the emergency department of 18 U.S. Level 1 trauma centers with suspected TBI- who has also received a negative CT scan- to determine if the brain-specific glial fibrillary acidic protein (GFAP) can be used to detect
• In the TRACK-TBI study- Abbott’s utilized its i-STAT Alinity device- evaluating the GFAP- then reviewing MRI scans taken ~2wks. later to confirm the TBI resulted in 64% of people with high GFAP were confirmed brain injury through an MRI scan- even with negative CT scan
• Abbott’s Alinity device is a portable blood analyzer with its blood test which is in development and is poised to be the first point-of-care blood test- providing results to doctors in 15 minutes

Click here to­ read full press release/ article

| Ref: Abbott | Image:  Abbott